Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zevra Therapeutics (ZVRA) Receivables - Other: 2015-2024

Historic Receivables - Other for Zevra Therapeutics (ZVRA) over the last 8 years, with Dec 2024 value amounting to $333,000.

  • Zevra Therapeutics' Receivables - Other fell 73.53% to $333,000 in Q4 2024 from the same period last year, while for Dec 2024 it was $333,000, marking a year-over-year decrease of 73.53%. This contributed to the annual value of $333,000 for FY2024, which is 73.53% down from last year.
  • Latest data reveals that Zevra Therapeutics reported Receivables - Other of $333,000 as of FY2024, which was down 73.53% from $1.3 million recorded in FY2023.
  • In the past 5 years, Zevra Therapeutics' Receivables - Other registered a high of $1.3 million during FY2023, and its lowest value of $107,000 during FY2021.
  • Its 3-year average for Receivables - Other is $901,667, with a median of $1.1 million in 2022.
  • Per our database at Business Quant, Zevra Therapeutics' Receivables - Other soared by 941.12% in 2022 and then plummeted by 73.53% in 2024.
  • Zevra Therapeutics' Receivables - Other (Yearly) stood at $137,000 in 2020, then decreased by 21.90% to $107,000 in 2021, then spiked by 941.12% to $1.1 million in 2022, then climbed by 12.93% to $1.3 million in 2023, then crashed by 73.53% to $333,000 in 2024.